多靶点粪便DNA检测在社区临床实践中的效用
该回顾性队列研究纳入35家基层医疗机构中2019年冬至2023年春开具多靶点粪便DNA(MT-sDNA)检测的患者,评估其诊断性能及阳性后结肠镜发现。482例(15%)MT-sDNA阳性,其中277例(57%)接受了随访结肠镜检查,253例有完整结肠镜数据;10例(4%)检出结直肠癌,61例(24%)检出进展期腺瘤,184例(73%)两者均无。结直肠癌检出率低于筛查队列预期,多数完成检测者为进展期腺瘤或结直肠癌的假阳性结果。
要点
- 482例MT-sDNA阳性患者中277例(57%)接受随访结肠镜,253例有完整数据。
- 253例中10例(4%)检出结直肠癌,61例(24%)检出进展期腺瘤,184例(73%)两者均无。
- 结直肠癌检出率在开具检测患者中为0.2%(10/5,827),在完成检测者中为0.3%(10/3,119)。
核心结论
- 在平均风险人群中,基于MT-sDNA的筛查有效性存疑,结直肠癌检出率低于筛查队列预期,且多数完成检测者为假阳性。
研究设计与样本
- 回顾性队列研究,纳入2019年冬至2023年春在35家网络基层医疗机构接受MT-sDNA检测(Cologuard)的患者电子健康记录数据。
- 排除高危患者及既往有结肠镜检查或既往MT-sDNA阴性结果者。
- 5,827例患者开具MT-sDNA检测,其中3,119例完成检测。
主要发现
- 3,119例完成检测者中482例(15%)MT-sDNA阳性,多数为女性,平均年龄65岁,以白人为主。
- 482例阳性者中277例(57%)接受随访筛查结肠镜,253例有完整结肠镜数据。
- 253例中10例(4%)检出结直肠癌,61例(24%)检出进展期腺瘤,184例(73%)两者均无。
- 结直肠癌最常见于乙状结肠,10例中8例为肿瘤、淋巴结、转移分期≥1的结直肠癌。
- 结直肠癌检出率在开具检测患者中为10/5,827(0.2%),在完成检测者中为10/3,119(0.3%),低于筛查队列预期。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Multitarget stool DNA (MT-sDNA) tests (i.e., Cologuard) serve as screening tests for colorectal cancer (CRC) and are recommended by the US Preventive Services Task Force every 1-3 years. In this study, in a primary care setting, our aim was to evaluate the diagnostic performance of MT-sDNA testing and colonoscopy findings after a positive MT-sDNA testing result. METHODS: This was a retrospective cohort study of electronic health record data including all patients who underwent MT-sDNA tests (Cologuard; Exact Sciences, Madison, WI) at 35 network primary care facilities from Winter of 2019 to Spring of 2023. Patients who were at high risk and had a prior colonoscopy or prior negative MT-sDNA test result were excluded. Assessment of pathology was as previously described, including for advanced adenomas and CRC. RESULTS: Among the 5,827 patients for whom MT-sDNA testing was ordered, 3,119 patients completed the test; 482 (15%) had a positive MT-sDNA test, most of whom were women, had an average age of 65 years, and were predominantly White (Supplemental Figure 1, Table 1). Among these 482 patients, 277 (57%) had a follow-up screening colonoscopy, with 253 patients having complete colonoscopy data. Ten patients (4%) had CRC, 61 (24%) had advanced adenomas, and 184 patients (73%) had neither. The sigmoid colon was the most common site for CRC, with 8 of 10 patients having tumor, node, metastasis stage ≥1 CRC. DISCUSSION: The rate of colon cancer detection (10/5,827 [0.2%] patients for whom it was ordered and 10/3,119 [0.3%] who completed the test) was lower than expected in a screening cohort. Most patients who completed MT-sDNA testing had a false-positive result for advanced adenomas or CRC (73%). Together, these findings raise questions about the effectiveness of screening based on MT-sDNA testing in an average risk population.
引用
- Rao AK, Kalra S, Tran D, et al. The Utility of Multitarget Stool DNA Testing in Community-Based Clinical Practice. Am J Gastroenterol. 2025. PMID: 40197618. doi:10.14309/ajg.0000000000003480
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。